{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-126400","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.965370+00:00","generated_at":"2026-06-07T11:37:13.842492+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eloxx amends Hercules loan, repays $1M; cash covenant lowered to $1.05M through Jan 2024","bullets":["Minimum qualified cash reduced to $1.05M from Dec 15, 2023 to Jan 25, 2024.","Company repaid $1.0M of principal; remaining Term Loan principal is $3.1M.","After Jan 25, minimum cash reverts to $1.05M plus accounts payable unpaid over 180 days.","Amendment provides temporary liquidity relief amid cash constraints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-126400","json":"https://secwatch.observer/filing/0001104659-23-126400.json","markdown":"https://secwatch.observer/filing/0001104659-23-126400.md","text":"https://secwatch.observer/filing/0001104659-23-126400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/tm2332971d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:37:13.842492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc51dff4ececd7ff1eb71a0e7bd7da8422962260","claim":"Eloxx Pharmaceuticals, Inc. amended credit facility of reducing the remaining outstanding principal of Term Loan Advances to $3.1 million with Hercules Capital, Inc., Hercules Capital IV, L.P..","evidence_excerpt":"the Company has repaid $1.0 million of the outstanding principal (without incurring a prepayment premium), reducing the remaining outstanding principal of Term Loan Advances to $3.1 million. The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Fourth Amendment, a copy","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"reducing the remaining outstanding principal of Term Loan Advances to $3.1 million"},{"label":"Counterparty","value":"Hercules Capital, Inc., Hercules Capital IV, L.P."},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"223f0f8f280ddfdc8848e2bf93a01196c0a8f0c2","claim":"Eloxx Pharmaceuticals, Inc. amended Fourth Amendment with Hercules Capital, Inc. valued at $1.0 million (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fourth Amendment to the Loan and Security Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Value","value":"$1.0 million"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}